Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23


69P - HER2 status in RAS and BRAF wild-type metastatic colorectal cancer - Portuguese study


06 Oct 2021




Maria Joao de Sousa


Annals of Oncology (2021) 32 (suppl_6): S1345-S1371. 10.1016/annonc/annonc740


M.J.P. de Sousa1, T. Fraga2, J. Correia Magalhães2, R. Basto2, J. Paulo2, P. Jacinto2, N. Bonito2, J.P. Magalhães2, P. Figueiredo2, G. Sousa2

Author affiliations

  • 1 Instituto Portugues Oncologia de Coimbra Francisco Gentil E. P. E. (IPO Coimbra), Coimbra/PT
  • 2 Instituto Portugues Oncologia de Coimbra Francisco Gentil E. P. E. (IPO Coimbra), 3000-075 - Coimbra/PT

Abstract 69P


Colorectal cancer (CRC) is the second most deadly cancer worldwide but currently there are few precision treatments available. Amplification/overexpression of HER2 (HER2+) is a well-established therapeutic target in breast and gastric cancer. HER2+ is present in approximately 5% of CRC and has been implicated in resistance to therapy with anti-epidermal growth factor receptor antibodies. The aim of our study was to evaluate HER2 status in RAS and BRAF wild-type metastatic CRC (mCRC) and its correlation with survival outcomes.


We performed a single-centre retrospective analysis of RAS and BRAF wild-type mCRC patients undergoing systemic treatment from July 2014 to September 2020. Tissue HER2 status was determined by performing immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH) and/or chromogenic in situ hybridization (CISH). HER2+ was defined as either IHC3 (+) or IHC2 (+) through FISH or CISH (+).


Fifty-nine patients were included. Four patients had HER2+ tumors (7%). The median age was 68 years (range 54-72). The majority of HER2+ mCRC occurred in males (n=3) and left-sided CRC (n=3). All patients received FOLFIRI plus Cetuximab as first-line treatment. At a median follow-up of 24.0 months, patients with HER2 negative mCRC presented with a median overall survival (OS) of 45.1 months (95% confidence interval [CI] 32.7-46.0). The four patients with HER2+ mCRC presented with an OS of 18.4 months, 20.4 months, 29.6 months, and 30.2 months.


To our knowledge, this is the first study reporting HER2+ in mCRC patients in a Portuguese population and the HER2+ rate was consistent with previous studies. Our study suggests that HER2+ may potentially be a marker that is able to predict poor prognosis in RAS and BRAF wild-type mCRC. There is potential that with the continued evolution of data in this area, HER2 may become a validated therapeutic target.

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.